My Web Dashboard





SEO News: Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine (FinanzNachrichten)

GENEVA, Switzerland, January 16 /PRNewswire-FirstCall/ -- Merck Serono ( Nachrichten ) (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety of Merck Serono's proprietary oral formulation of cladribine for the treatment of relapsing ...

read more...

Related News